Table 1.
Characteristics of the patients with EGPA at the time of mepolizumab initiation*
| Overall | Mepolizumab 100 mg/4 weeks | Mepolizumab 300 mg/4 weeks | P | |
|---|---|---|---|---|
| (n = 203) | (n = 158) | (n = 33) | ||
| Female | 116 (57.1) | 88 (55.7) | 22 (66.7) | 0.333 |
| Smoking status | ||||
| Former | 44 (21.7) | 36 (22.8) | 5 (15.2) | 0.640 |
| Current | 3 (1.5) | 3 (1.9) | 0 | |
| Age at diagnosis, median (IQR) years | 49.1 (37.7–57.1) | 48.7 (37.9–57.5) | 49.2 (39.8–53.4) | 0.380 |
| Age at mepolizumab initiation, median (IQR) years | 55.1 (46.7–62.5) | 55.1 (46.7–62.8) | 53.0 (47.3–59.3) | 0.426 |
| Disease duration at mepolizumab initiation, median (IQR) years | 4.8 (4.9–9.2) | 4.9 (1.6–8.9) | 3.9 (1.1–14.1) | 0.921 |
| Active organ involvement at mepolizumab initiation | ||||
| Constitutional | 56 (27.6) | 50 (31.7) | 3 (9.1) | 0.009 |
| Purpura | 15 (7.4) | 11 (7.0) | 2 (6.1) | 1.000 |
| ENT | 145 (71.4) | 121 (76.6) | 17 (51.5) | 0.005 |
| Pulmonary | 182 (89.7) | 141 (89.2) | 29 (87.9) | 0.765 |
| Cardiac | 10 (4.9) | 8 (5.1) | 1 (3.0) | 1.000 |
| Gastrointestinal | 9 (4.4) | 8 (5.1) | 1 (3.0) | 1.000 |
| Renal | 5 (2.5) | 5 (3.2) | 0 | NA |
| Peripheral neurologic | 46 (22.7) | 36 (22.8) | 6 (18.2) | 0.650 |
| Active disease at mepolizumab initiation (BVAS >0) | 187 (92.1) | 144 (91.1) | 31 (93.9) | 0.792 |
| BVAS score at mepolizumab initiation, median (IQR) | 4 (2–8) | 4 (2–8) | 4 (2–7) | 0.163 |
| Laboratory parameters at mepolizumab initiation† | ||||
| ANCA positive | 38 (20.0) | 28 (18.9) | 9 (27.3) | 0.339 |
| Perinuclear ANCA | 34 (17.9) | 26 (17.6) | 8 (24.2) | |
| Cytoplasmic ANCA | 4 (2.1) | 2 (1.4) | 1 (3.0) | |
| MPO ANCA | 34 (17.9) | 27 (18.2) | 8 (24.2) | |
| PR3 ANCA | 4 (2.1) | 2 (1.4) | 1 (3.0) | |
| Eosinophil count, median (IQR)‡ | 610 (200–1,040) | 700 (200–1,080) | 440 (200–910) | 0.328 |
| Pharmacologic therapies administered before mepolizumab initiation | ||||
| Oral glucocorticoids | 201 (99.0) | 156 (98.7) | 33 (100.0) | NA |
| Azathioprine | 91 (44.8) | 69 (43.7) | 17 (51.5) | 0.446 |
| Methotrexate | 78 (38.4) | 56 (35.4) | 18 (54.6) | 0.050 |
| Cyclophosphamide | 57 (28.1) | 44 (27.9) | 11 (33.3) | 0.531 |
| Mycophenolate | 39 (19.2) | 29 (18.4) | 6 (18.2) | 1.000 |
| Cyclosporine | 21 (10.3) | 18 (11.4) | 1 (3.0) | 0.206 |
| Rituximab | 39 (19.2) | 36 (22.8) | 3 (9.1) | 0.097 |
| IV immunoglobulin | 18 (8.9) | 17 (10.8) | 1 (3.0) | 0.321 |
| Omalizumab | 17 (8.4) | 13 (8.2) | 2 (6.1) | 1.000 |
| Other immunosuppressants | 16 (7.9) | 13 (8.2) | 1 (3.0) | 0.471 |
| Pharmacologic therapies at mepolizumab initiation | ||||
| Prednisone equivalent daily dose in the previous 3 months, median (IQR)§ | 10 (5–20) | 10 (IQR 5‐20) | 10 (IQR 5‐22.5) | 0.854 |
| Oral glucocorticoids | 194 (95.6) | 149 (94.3) | 33 (100.0) | NA |
| Prednisone equivalent daily dose, median (IQR) | 10 (5–20) | 10 (5–20) | 10 (5–25) | 0.511 |
| Methotrexate | 38 (18.7) | 29 (18.4) | 9 (27.3) | 0.240 |
| Azathioprine | 23 (11.3) | 19 (12.0) | 3 (9.1) | 0.772 |
| Mycophenolate | 18 (8.9) | 12 (7.6) | 4 (12.1) | 0.486 |
| Cyclosporine | 2 (1.0) | 1 (0.6) | 0 | NA |
| Rituximab | 23 (11.3) | 20 (12.7) | 3 (9.1) | 0.771 |
| IV immunoglobulin | 12 (5.9) | 11 (7.0) | 1 (3.0) | 0.695 |
| Other immunosuppressants | 5 (2.5) | 3 (1.9) | 1 (3.0) | 0.535 |
| Inhaled therapy for asthma | 192 (95.0) | 150 (94.9) | 30 (90.9) | 0.407 |
Except where indicated otherwise, values are the number (%). EGPA = eosinophilic granulomatosis with polyangiitis; IQR = interquartile range; ENT = ear, nose, and throat; NA = not applicable; BVAS = Birmingham Vasculitis Activity Score; ANCA = antineutrophil cytoplasmic antibody; MPO = myeloperoxidase; PR3 = proteinase 3; IV = intravenous.
Data were available for 190 patients overall, 148 patients receiving mepolizumab 100 mg/4 weeks, and 33 patients receiving mepolizumab 300 mg/4 weeks.
Data were available for 194 patients overall, 152 patients receiving mepolizumab 100 mg/4 weeks, and 32 patients receiving mepolizumab 300 mg/4 weeks.
Data were available for 195 patients overall, 151 patients receiving mepolizumab 100 mg/4 weeks, and 32 patients receiving mepolizumab 300 mg/4 weeks.